Keyword: Roger Perlmutter
Merck's planned spinoff will allow the company to focus on oncology and other fast-growing sectors, CEO Ken Frazier said. Analysts aren't convinced.
Wall Street analysts pressed Merck for details about whether Keytruda can maintain strong growth as it faces rivals in lung and breast cancer.
Merck just keeps churning out positive data from its chemo-oriented approach to immuno-oncology combination therapy.
Merck's sales of cancer drug Keytruda more than doubled during the first quarter, but analysts were expecting more.